Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

83.54 -0.82 (-0.97%)
Streaming Delayed Price Updated: 12:26 PM EDT, Oct 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,079,155
Open 83.40
Bid (Size) 83.53 (3)
Ask (Size) 83.55 (1)
Prev. Close 84.36
Today's Range 82.88 - 84.05
52wk Range 61.24 - 84.61
Shares Outstanding N/A
Dividend Yield 1.23%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Healthcare Sector Navigates Turbulent Waters as Drug Pricing Agreements Reshape Market Landscape
September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk
The U.S. pharmaceutical industry is at the center of a policy maelstrom. 
Via Benzinga
Topics ETFs

Performance

YTD
+26.8%
+26.8%
1 Month
+4.2%
+4.2%
3 Month
+17.4%
+17.4%
6 Month
+15.7%
+15.7%
1 Year
+6.2%
+6.2%

More News

Read More
AstraZeneca Plans Ordinary Share Listing In US – Find Out More On The Harmonized Listing Structure
Via Stocktwits
AstraZeneca's Strategic Listing Harmonization: A Unified Global Platform for Growth
Via MarketMinute
Topics Economy
GSK Leaps Into Buy Zone On Surprise Departure Of CEO Emma Walmsley
Via Investor's Business Daily
AstraZeneca Moves From ADRs To NYSE Listing
Via Benzinga
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in DESTINY-Breast05 Phase III trial
From AstraZeneca
Via Business Wire
3 Magnificent Stocks Under $100 to Buy Right Now
Via The Motley Fool
Your AstraZeneca Medicine Could Be Cheaper As Much As 70%
Via Benzinga
AstraZeneca launches direct-to-consumer platform to expand access to medications for US patients, including those living with chronic conditions
From AstraZeneca
Via Business Wire
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet
Via Benzinga
Topics Government World Trade
Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America
Via Stocktwits
Topics Government
Moderna Stands By UK As Pharma Giants Criticize Pricing, UK Secures First Onshore mRNA Vaccine Production Centre
Via Benzinga
United Kingdom The Worst European Country For Drug Prices: Eli Lilly CEO
Via Benzinga
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer
From AstraZeneca
Via Business Wire
European Advisory Panel Recommends Two AstraZeneca Drugs For Approval
Via Benzinga
Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market
Via MarketMinute
Topics Economy Intellectual Property
Is the Market Bullish or Bearish on AstraZeneca?
Via Benzinga
Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era
Via MarketMinute
Lilly's $5 Billion Virginia Investment: A Game Changer for GLP-1 and Oncology Drug Production
Via MarketMinute
Topics Artificial Intelligence Economy Government
Eli Lilly Poised for Blockbuster Q3 2025 with Skyrocketing EPS and Revenue Projections
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes
Via MarketMinute
AIRSUPRA® (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol
From AstraZeneca
Via Business Wire

Frequently Asked Questions

Is AstraZeneca PLC - American Depositary Shares publicly traded?
Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.
What exchange does AstraZeneca PLC - American Depositary Shares trade on?
AstraZeneca PLC - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?
The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the Nasdaq Stock Market
What is the current price of AstraZeneca PLC - American Depositary Shares?
The current price of AstraZeneca PLC - American Depositary Shares is 83.54
When was AstraZeneca PLC - American Depositary Shares last traded?
The last trade of AstraZeneca PLC - American Depositary Shares was at 10/02/25 12:26 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.